weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration resistant prostate cancer. Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Clemons, Mark J
  • Ong, Michael
  • Stober, Carol
  • Ernst, D Scott
  • Booth, Christopher M
  • Canil, Christina M
  • Mates, Mihaela
  • Robinson, Andrew George
  • Blanchette, Phillip S
  • Joy, Anil Abraham
  • Hilton, John Frederick
  • Aseyev, Olexiy
  • Pond, Gregory
  • Hutton, Brian
  • Jeong, Ahwon
  • Vandermeer, Lisa
  • Fergusson, Dean

publication date

  • May 20, 2019